Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Jul 12, 2023
Boost gain with AI bot 6.82% PROFIT for SAVA Amid Bearish Trends: An In-Depth Analysis

Boost gain with AI bot 6.82% PROFIT for SAVA Amid Bearish Trends: An In-Depth Analysis

In an unexpected twist of events last week, SAVA, a high-flying stock in the pharmaceutical sector, saw a considerable profit surge of 6.82%. This performance can be attributed to the artificial intelligence (AI) trading robot's strategic buying and selling decisions. This unexpected success occurred despite the overall bearish trend suggested by the technical indicators. Let's delve deeper into the details of this phenomenon.

Analyzing the Cross of Moving Averages:

The moving averages of stock prices are key indicators used by investors to assess market trends. On July 6, 2023, the 10-day moving average for SAVA crossed below the 50-day moving average, a bearish signal. This crossing generally indicates a downward shift in the stock's trend, often prompting investors to consider selling their holdings.

This signal, referred to as a 'death cross,' typically triggers a sell signal among traditional investors. Historically, in 16 of 16 past instances when SAVA's 10-day moving average crossed below its 50-day counterpart, the stock continued to move higher over the subsequent month. Based on this historical pattern, the odds of a continued downward trend are pegged at 90%.

Contrarian Performance:

Contrary to expectations, however, SAVA posted a 6.82% profit last week. This remarkable performance, particularly in light of the prevailing bearish indicators, has turned quite a few heads in the financial sector. So, what drove this contrary market movement? The answer lies in the AI trading robot that has been managing part of SAVA's trading operations.

The Role of AI:

The AI trading robot, with its advanced machine learning algorithms, has the capacity to analyze complex data and identify profitable trade opportunities that may not be apparent or accessible to human investors. These AI systems can use a vast array of factors and indicators to make buy and sell decisions, often in fractions of a second. They can process massive volumes of data, allowing for a depth and speed of analysis that surpasses human capabilities.

Notably, these trading robots can make predictions and decisions outside the human cognitive biases' realm. It's possible that the AI analyzed the historical data, spotted the recurring pattern, and anticipated the price rise despite the bearish cross. It is this capacity for high-speed, high-volume data analysis and the ability to execute transactions at opportune moments that likely led to SAVA's profit surge.

The 6.82% profit generated by SAVA last week, despite the bearish market signals, serves as a testament to the potential of AI in trading and investment. It underscores the value of combining traditional trading strategies with AI capabilities to navigate the complexities of today's financial markets effectively. While technical analysis is a potent tool in a trader's arsenal, AI's prowess in pattern recognition and predictive analytics is pushing the boundaries of what's possible in financial trading.

This case serves as a reminder to investors and traders alike that relying solely on traditional signals may not always yield the desired results. Incorporating AI and machine learning strategies into trading operations could be the key to unlocking new profit potentials, even in seemingly bearish market conditions.

Related Ticker: FLNA

FLNA's RSI Indicator slumps into oversold zone

The RSI Indicator for FLNA moved into overbought territory on September 04, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

FLNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLNA as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FLNA turned negative on September 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FLNA entered a downward trend on August 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.627) is normal, around the industry mean (20.539). P/E Ratio (0.000) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.187).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. FLNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.33B. The market cap for tickers in the group ranges from 58 to 138.42B. VRTX holds the highest valuation in this group at 138.42B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 2,397%. ONCO experienced the highest price growth at 67%, while VBIO experienced the biggest fall at -96%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 16%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was -0%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 53
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
FLNA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of novel drugs

Industry Biotechnology

Profile
Details
Industry
Pharmaceuticals Other
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interact to see
Advertisement
Shares of Citigroup (C) declined approximately 5.17% in the most recent completed trading session, closing at $110.19 versus a prior close of $116.19. The primary catalyst was hotter-than-expected U.S. Producer Price Index (PPI) data, stoking fears of persistent inflation and a reduced likelihood of near-term Federal Reserve rate cuts.
AVAV surged +16.83% in Monday's session, trading at $294.70 compared to Friday's closing price of $252.25 — a gain of $42.45 per share. The primary catalyst was a powerful confluence of geopolitical demand and corporate developments: the escalating U.S.-Iran military conflict dramatically amplified investor focus on AeroVironment's loitering munitions portfolio.
Shares of Venture Global surged approximately +16.61% on March 2, 2026, closing at $11.30 compared to the prior close of $9.69. The primary catalyst was a stronger-than-expected Q4 2025 earnings report, with GAAP EPS of $0.41 beating the consensus estimate of $0.36 by $0.05.
Shares of CCL plunged 10.11% in Monday's session, falling from a prior close of $31.55 to $28.36. The primary catalyst was a coordinated U.S. and Israeli military strike on Iran over the weekend, causing crude oil prices to surge approximately 8–9% and triggering a global risk-off selloff.
ADT shares dropped sharply — falling as much as 13.4% intraday and hitting a new 52-week low of $6.65 — after reporting Q4 2025 results before the Monday open. Fourth-quarter revenue and guidance both missed analyst expectations, overshadowing an earnings-per-share beat.
Shares of Karman Holdings surged approximately +13.00% in Monday's session, closing near $99.57, up from a prior close of $88.11. The primary catalyst was the release of the company's fourth-quarter and full-year 2025 financial results, which showed strong revenue growth and exceeded top-line expectations.
Netflix dropped out of a months‑long bidding war for Warner Bros Discovery after Paramount/Skydance raised their offer, and Netflix refused to match it, saying the new price was “no longer financially appealing.” The stock jumped roughly 10%+ on the news as investors read this as fiscal discipline—management chose not to overpay, which protects the balance sheet and future returns instead of chasing scale at any price.
SE shares plunged approximately 23% at Tuesday's open, marking one of the steepest single-session selloffs in recent company history. The primary catalyst was a severe Q4 2025 earnings miss: adjusted EPS of $0.63 fell well short of the analyst consensus of $0.80, a miss of roughly 21%.
Shares of Southern Copper Corporation (SCCO) are down 10.32% in Tuesday's session, trading at $196.27 versus the prior close of $218.85 — a single-day loss of $22.58 per share. The primary catalyst is a Bank of America downgrade issued on March 2, cutting SCCO from Neutral to Underperform, which triggered accelerating sell pressure into Tuesday's open.
MDB shares plummeted approximately 26.44% on March 3, 2026, closing around $238.24, down from a prior close of approximately $322.55. The primary catalyst was weaker-than-expected fiscal Q1 2027 guidance, with non-GAAP EPS projected at $1.15–$1.19 versus analyst expectations of roughly $1.46.
Shares of Battalion Oil Corporation (BATL) are surging approximately +130% in Tuesday's session, with the stock hitting a fresh 52-week high as of intraday trading on March 3, 2026. The dominant catalyst is a sharp escalation of U.S.-Israel-Iran military tensions, with Tehran restricting access to the Strait of Hormuz — triggering a spike in crude oil futures and a broad-based energy sector rally.
Shares of CRDO dropped 18.55% on March 3, 2026, falling from a prior close of $114.22 to approximately $93.03. The primary catalyst was a "sell the news" reaction to fiscal Q3 2026 earnings — despite beating consensus estimates on both revenue and EPS, the market sold off on forward margin compression guidance.
PSIX shares plummeted approximately 25.37% on March 3, 2026, closing near $64.00 versus the prior session's close of $85.75. The primary catalyst was the company's Q4 and full-year 2025 earnings report, which revealed Q4 net income fell 31% year-over-year to $16.1 million despite a 33% revenue increase.
Life360 Inc Common (LIF) stunned many traders today as the stock slid more than 20% despite reporting what, on the surface, looked like very strong results: revenue up roughly 32% year over year to about $489.5 million and the company’s first-ever full‑year profitability.
StoneCo Ltd. (STNE) shares dropped more than 15% today after the market reacted negatively to the company’s latest Q4 2025 and full‑year results and its updated outlook. While StoneCo delivered year‑over‑year revenue and earnings growth and even topped EPS expectations, investors focused on weaker‑than‑hoped revenue numbers, rising credit risk metrics, and a more cautious medium‑term guidance profile, which together triggered a sharp rerating of the stock.
Alamo Group reported Q4 2025 EPS of about 1.70 dollars, well below analyst expectations that were in the low‑2 dollar range, producing a sizable negative earnings surprise. Quarterly revenue came in around 373.7 million dollars, down roughly 3% year over year and about 7–8% below consensus estimates near 405 million dollars, signaling softer demand than the market anticipated.
Hycroft Mining Holding Corp (HYMC) shares slid more than 12% today as traders digested the company’s newly filed 2025 annual report, a major corporate update, and an extended development timeline that shifts the story further away from near‑term production and cash flow.
PicS (PICS) shares dropped more than 12% today as investors reacted to mounting concerns about valuation, elevated volatility, and uncertainty ahead of the company’s next earnings report later in March.
Shares of MOBX surged approximately +532.77% in the March 3, 2026 trading session, closing at $1.12 versus a prior close of $0.18. The primary catalyst was a major production purchase order from the U.S. Navy for components used in the Tomahawk cruise missile program.
DAKT shares are declining approximately -10% in Wednesday's session, trading near $23.91, compared to the prior close of approximately $26.57. The primary catalyst is the pre-market release of fiscal Q3 2026 earnings, in which diluted EPS of $0.06 fell significantly short of the consensus estimate of approximately $0.13–$0.15.